Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.

You may also be interested in...



Merck’s Insomnia Agent Gaboxadol Shows Promising Phase II Results

The firm has highlighted the GABA-A receptor agonist as a standout result from its recent in-licensing deals.

Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME

The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.

Sandoz Looks To Biosimilars As It Reprioritizes In The US

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Topics

UsernamePublicRestriction

Register

PS065824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel